NCT06251258

Brief Summary

Introduction Chronic insomnia is a prevalent disorder in the general population, affecting up to 20% according to French National Institute of Health and Medical Research, leading to a decline in quality of life and an increased risk of developing certain psychiatric disorders, notably major depressive episodes. Chronic insomnia, particularly when accompanied by reduced sleep duration, has been associated with cognitive impairments documented in the literature, such as reduced concentration, working memory, vigilance, and certain executive functions. While some studies suggest subjective cognitive impairment in insomnia, it remains inconclusive when objectively measured. Individuals with chronic insomnia often report a global deterioration in social life, characterized by irritability, attentional difficulties, asthenia, and social isolation. This raises questions about potential impairments in social abilities, particularly in recognizing facial emotions, which may be linked to the subjective complaints of reduced quality of life in individuals with insomnia. Several studies have explored facial emotion recognition in insomnia, with some indicating impairments in emotion recognition or evaluation of emotion intensity. Others demonstrated deficits in recognizing specific emotions (such as anger) or representations (such as fatigue), which were associated with attentional deficits and changes in visual fixation points in eye-tracking studies. However, some authors found no significant association between insomnia complaints and impaired facial emotion recognition. Facial emotion recognition has been studied using eye-tracking in major depressive episodes, attention-deficit/hyperactivity disorder (ADHD), and autism spectrum disorders. Eye-tracking studies have revealed attentional biases toward negative emotions in depression and deficits in visual attention to the eye region in autism, contributing to impaired facial emotion recognition. To date, no study has compared facial emotion recognition abilities between individuals with insomnia and a control group, considering attentional deficits and emotional dysregulation described in insomnia. Methods The study aims to compare two groups: one with isolated insomnia (without associated psychiatric disorders) and a control group (without insomnia or psychiatric disorders). Patients with psychiatric or addictive disorders will be excluded based on Diagnostic and Statistical Manual of Mental Disorders, version 5 (DSM-V) psychiatric interviews. Participants aged over 65 or under 18 will also be excluded to mitigate potential biases related to dementia and cognitive alterations not related to insomnia. The insomnia group will consist of individuals seeking care at the Sleep Center of Angers University Hospital for chronic insomnia (lasting more than 3 months). Insomnia will be confirmed using the Insomnia Severity Index (ISI), with a score exceeding 15, while individuals with subclinical insomnia (ISI score between 7 and 15) will be excluded. The control group will have an ISI score below 7 (indicating the absence of insomnia). The main objective is to determine whether facial emotion recognition differs between the insomnia and control groups. Secondary objectives include assessing differences between explicit facial emotion recognition tests (controlled conditions) and eye-tracking tests (implicit memory) in both groups to evaluate attentional biases. Additionally, the study aims to explore differences in facial emotion recognition tests based on emotional regulation profiles (adaptive or non-adaptive regulation). Expected Results The hypothesis is that facial emotion recognition under controlled conditions (explicit memory) will not differ between the insomnia and control groups. However, differences are expected in implicit memory tests (eye-tracking) due to the attentional deficits previously described in insomnia. Additionally, variations in facial emotion recognition are anticipated based on emotional regulation profiles, which may influence facial emotion recognition in insomnia. The study's findings could contribute to a better understanding of cognitive complaints related to insomnia, especially in the realm of social interactions, by objectively assessing and specifying potential biases. This research may also inform targeted therapeutic approaches, particularly in cognitive-behavioral therapy, focusing on cognitive remediation and restructuring. Ultimately, the study's outcomes could guide the development of specific rehabilitation programs centered on facial emotion recognition, emotional deficits, and emotional dysregulation in insomnia.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
128

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2025

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 16, 2024

Completed
24 days until next milestone

First Posted

Study publicly available on registry

February 9, 2024

Completed
1.1 years until next milestone

Study Start

First participant enrolled

March 1, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2025

Completed
Last Updated

February 24, 2025

Status Verified

February 1, 2025

Enrollment Period

7 months

First QC Date

January 16, 2024

Last Update Submit

February 21, 2025

Conditions

Keywords

chronic insomnianeuropsychologyfacial expression assessmentemotional regulation

Outcome Measures

Primary Outcomes (3)

  • Facial emotion recognition test (TREF test) in insomnia and control

    The error rate on facial recognition test (in percent)

    10 minutes

  • Facial emotion recognition test (TREF test) in insomnia and control

    The intensity of the emotion on facial recognition test (in percent)

    10 minutes

  • Facial emotion recognition test (TREF test) in insomnia and control

    Response time on facial recognition test (in second)

    10 minutes

Secondary Outcomes (7)

  • Attentional bias

    10 minutes

  • Attentional bias

    10 minutes

  • Attentional bias

    10 minutes

  • Attentional bias

    10 minutes

  • Attentional bias

    10 minutes

  • +2 more secondary outcomes

Study Arms (2)

Insomnia

EXPERIMENTAL
Diagnostic Test: Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)

Control

ACTIVE COMPARATOR
Diagnostic Test: Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)

Interventions

Facial emotion recognition test without eye-tracking (explicit test, without time limit) and facial emotion recognition test with eye tracking (implicit test, with observation of fixation points)

ControlInsomnia

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18 and 65
  • Signed consent to participate in the study
  • Person affiliated to or benefiting from a social security scheme
  • For insomnia group: known insomnia (patient treated for insomnia)
  • Insomnia group: ISI \>14 (between 15 and 28 = clinical insomnia)
  • Control group: ISI \< 8 (between 0 and 7 = no insomnia)
  • Known psychiatric disorders (Characterized depressive episode, Bipolar disorder, Schizophrenia and other delusional disorders, Specified anxiety disorder (social anxiety, generalized anxiety disorder), Obsessive-compulsive disorder (OCD), Eating disorders, Neurodevelopmental disorders (ASD, ADHD), Active addictive disorders (excluding tobacco), ...)
  • Taking antidepressant, neuroleptic or thymoregulator medication
  • Taking a benzodiazepine with a long half-life (\>12 hours)
  • Condition requiring hospitalization in the month preceding the study
  • Known sequelae or progressive neurological disease
  • Known significant ophthalmological condition
  • Pregnancy or breast-feeding
  • Person deprived of liberty by judicial or administrative decision
  • Person subject to a legal protection measure
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Sleep Initiation and Maintenance DisordersEmotional Regulation

Interventions

Eye-Tracking Technology

Condition Hierarchy (Ancestors)

Sleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental DisordersSelf-ControlSocial BehaviorBehavior

Intervention Hierarchy (Ancestors)

Eye Movement MeasurementsDiagnostic Techniques, OphthalmologicalDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosis

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 16, 2024

First Posted

February 9, 2024

Study Start

March 1, 2025

Primary Completion

September 30, 2025

Study Completion

September 30, 2025

Last Updated

February 24, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share